VEGFA and wet macular degeneration: Anti‐VEGF proteins have been the cornerstone of wet AMD therapeutics, and approved anti‐VEGF proteins include ranibizumab, aflibercept, conbercept, brolucizumab, and bevacizumab (off‐label use).8, 9, 10